wr 99210 has been researched along with folic acid in 2 studies
| Studies (wr 99210) | Trials (wr 99210) | Recent Studies (post-2010) (wr 99210) | Studies (folic acid) | Trials (folic acid) | Recent Studies (post-2010) (folic acid) |
|---|---|---|---|---|---|
| 59 | 0 | 12 | 30,001 | 1,945 | 10,195 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jacobus, DP; Kinyanjui, SM; Mberu, EK; Watkins, WM; Winstanley, PA | 1 |
| Freundlich, JS; Jung, H; Koo, MS; Kumar, A; Liao, R; Nandakumar, M; Nixon, MR; Rhee, KY; Roberts, JP; Rustad, T; Sacchettini, JC; Saionz, KW; Sherman, DR; Szymonifka, MJ | 1 |
2 other study(ies) available for wr 99210 and folic acid
| Article | Year |
|---|---|
The antimalarial triazine WR99210 and the prodrug PS-15: folate reversal of in vitro activity against Plasmodium falciparum and a non-antifolate mode of action of the prodrug.
Topics: Animals; Antidotes; Antimalarials; Asia, Southeastern; Dose-Response Relationship, Drug; Drug Resistance; Folic Acid; Folic Acid Antagonists; Hematinics; Humans; Inhibitory Concentration 50; Kenya; Leucovorin; Malaria, Falciparum; Plasmodium falciparum; Prodrugs; Proguanil; Triazines | 1999 |
Folate pathway disruption leads to critical disruption of methionine derivatives in Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Dihydropteroate Synthase; Drug Evaluation, Preclinical; Drug Synergism; Folic Acid; Folic Acid Antagonists; Gene Expression Regulation, Bacterial; Humans; Methionine; Mycobacterium tuberculosis; S-Adenosylmethionine; Species Specificity; Tetrahydrofolate Dehydrogenase; Triazines | 2014 |